Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786585 | 0.83 | ALDH1A1 (0.63) | HPGDSKDM4EALDH1A1ACHEL3MBTL1 | |
| SCHEMBL2550713 | 0.81 | PDE10A (0.57) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL2547543 | 0.81 | ACHE (0.57) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL2552069 | 0.81 | ALDH1A1 (0.51) | ALDH1A1TLR7 | |
| SCHEMBL27740378 | 0.80 | ACHE (0.55) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL9823339 | 0.79 | EGLN1 (0.53) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL28780113 | 0.79 | ACHE (0.54) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL6122013 | 0.78 | KDM4E (0.54) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL22792368 | 0.77 | KDM4E (0.50) | HPGDSKDM4EALDH1A1ACHETLR7 | |
| SCHEMBL352152 | 0.77 | HPGDS (0.73) | HPGDSKDM4EALDH1A1ACHETLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3187490-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2022-04-06 | — | — | EP | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2011076678-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118503-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HPGDS 4601/4885KDM4E 1864/4885ALDH1A1 440/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HPGDS 4601/4885KDM4E 1864/4885ALDH1A1 440/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HPGDS 4601/4885KDM4E 1864/4885ALDH1A1 440/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | HPGDS 4601/4885KDM4E 1864/4885ALDH1A1 440/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | HPGDS 141/4885KDM4E 2243/4885ALDH1A1 1229/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | HPGDS 4601/4885KDM4E 1864/4885ALDH1A1 440/4885 |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | HPGDS 267/4885KDM4E 2232/4885ALDH1A1 178/4885 |
| US-20090118503-A1 | FAAH INHIBITORS | FAAH, FAAH2, CNR2 | HPGDS 139/4885KDM4E 1921/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.